Kemper Kathryn E, Augusto Orvalho, Gloyd Stephen, Akoku Derick A, Ouattara Gbossouna, Perrone Lucy A, Assoa Paul Henri, Akoua-Koffi Chantal, Adje-Toure Christiane, Koné Ahoua
Health Alliance International, Seattle, Washington, United States of America.
Department of Global Health, University of Washington, Seattle, Washington, United States of America.
PLOS Glob Public Health. 2023 Sep 14;3(9):e0001822. doi: 10.1371/journal.pgph.0001822. eCollection 2023.
Routine viral load (VL) monitoring is the standard of care in Côte d'Ivoire and allows for effective treatment guidance for people living with human immunodeficiency virus (HIV) to reach viral load suppression (VLS). For VL monitoring to be effective in reducing the impact of HIV, it must be provided in accordance with national guidance. This study aimed to evaluate VL testing, VLS rates and adherence to national guidance for VL testing using data collected from three national laboratories. We collected data on VL testing between 2015-2018 from OpenELIS (OE), an open-source electronic laboratory information system. We merged data by unique patient ID for patients (0-80 years old) who received multiple VL tests to calculate time between tests. We defined VLS as HIV RNA ≤1,000 copies/mL based on Côte d'Ivoire national and WHO guidance at the time of data collection. We used the Kaplan-Meier survival estimator to estimate time between ART (antiretroviral therapy) initiation and the first VL test, time between subsequent VL tests, and to estimate the proportion of people living with HIV (PLHIV) who were virally suppressed within 12 months of ART initiation. At the first documented VL test, 79.6% of patients were virally suppressed (95% CI: 78.9-80.3). Children under 15 were the least likely to be virally suppressed (55.2%, 95% CI: 51.5-58.8). The median time from ART initiation to the first VL sample collection for testing was 7.8 months (IQR:6.2-13.4). 72.4% of patients were virally suppressed within one year of treatment initiation (95% CI:71.5-73.3). Approximately 30% of patients received a second VL test during the 4-year study period. The median time between the first and second VL tests was 24.9 months (IQR: 4.7->40). Most PLHIV received their first VL test within the recommended 12 months of ART initiation but did not receive subsequent VL monitoring tests within the recommended time frame, reducing the benefits of VL monitoring. While VLS was fairly high, children were least likely to be virally suppressed. Our findings highlight the importance of regular VL monitoring after the first VL test, especially for children.
在科特迪瓦,常规病毒载量(VL)监测是标准治疗手段,可为感染人类免疫缺陷病毒(HIV)的患者提供有效的治疗指导,以实现病毒载量抑制(VLS)。为使VL监测有效降低HIV的影响,必须按照国家指南进行。本研究旨在利用从三个国家实验室收集的数据,评估VL检测、VLS率以及对国家VL检测指南的依从性。我们从开源电子实验室信息系统OpenELIS收集了2015年至2018年期间的VL检测数据。我们通过唯一患者ID对接受多次VL检测的患者(0至80岁)的数据进行合并,以计算检测之间的时间间隔。根据数据收集时科特迪瓦国家和世界卫生组织的指南,我们将VLS定义为HIV RNA≤1000拷贝/毫升。我们使用Kaplan-Meier生存估计器来估计抗逆转录病毒疗法(ART)开始与首次VL检测之间的时间、后续VL检测之间的时间,并估计在ART开始后12个月内病毒得到抑制的HIV感染者(PLHIV)的比例。在首次有记录的VL检测中,79.6%的患者病毒得到抑制(95%置信区间:78.9 - 80.3)。15岁以下儿童病毒得到抑制的可能性最小(55.2%,95%置信区间:51.5 - 58.8)。从ART开始到首次采集VL样本进行检测的中位时间为7.8个月(四分位间距:6.2 - 13.4)。72.4%的患者在治疗开始后一年内病毒得到抑制(95%置信区间:71.5 - 73.3)。在4年研究期间,约30%的患者接受了第二次VL检测。首次和第二次VL检测之间的中位时间为24.9个月(四分位间距:4.7 ->40)。大多数PLHIV在ART开始后的推荐12个月内接受了首次VL检测,但未在推荐时间框架内接受后续VL监测检测,从而降低了VL监测的益处。虽然VLS相当高,但儿童病毒得到抑制的可能性最小。我们的研究结果凸显了首次VL检测后定期进行VL监测的重要性,尤其是对儿童而言。